Superworth

Pfizer price to book ratio PFE

Market value divided by the book value of the company's net assets, since 2009.

Today, Nov 3, 2026
2.1×
10-year median
3.0×
Against its 10-year history
33rd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.4× to 4.4×
Peer median
8.6×

Pfizer's price to book ratio is 2.1× as of Nov 3, 2026.

That is below its ten-year median of 3.0×, lower than on 67% of days in the last ten years.

Over that time it ranged from 1.4× in May 2025 to 4.4× in Dec 2021.

The median for 8 large drugmakers of a similar size is 8.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.1×1.5×2.1×
20251.5×1.4×1.8×
20241.6×1.5×1.9×
20231.7×1.6×3.1×
20223.1×2.7×4.1×
20214.4×2.9×4.4×
20203.1×2.4×3.5×
20193.2×3.0×3.9×
20183.3×2.7×3.6×
20173.4×2.9×3.5×
20163.0×2.5×3.4×
20152.8×2.4×3.1×
20142.4×2.2×2.6×
20132.4×2.2×2.6×
20122.1×1.7×2.3×
20111.8×1.5×1.8×
20101.5×1.2×2.3×
20092.1×1.6×2.2×

Against its peers

Companies in Drug Manufacturers - General nearest Pfizer's size, closest first, today.

CompanyPrice to book ratio
PFEPfizer2.1×
GILDGilead Sciences16.4×
BMYBristol-Myers Squibb5.8×
AMGNAmgen21.6×
MRKMerck8.6×
ABBVAbbVien/m
JNJJohnson & Johnson7.7×
BIIBBiogen2.0×
LLYEli Lilly and39.8×
Peer median8.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Pfizer

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.